• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biohit

2.46 EUR

-2.77 %

4,933 following

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-2.77 %
+4.68 %
+2.50 %
-33.33 %
-33.33 %
-9.56 %
+31.55 %
+19.42 %
-52.69 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
37.41M EUR
Turnover
24.65K EUR
P/E (adj.) (26e)
16.86
EV/EBIT (adj.) (26e)
11.33
P/B (26e)
2.17
EV/S (26e)
1.75
Dividend yield-% (26e)
1.78 %
Coverage
Recommendation
Accumulate
Target price
3.50 EUR
Updated
12.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 15.01.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Nasdaq Company News Vertaisarvioitu tutkimus vahvistaa GastroPanel®-testin arvon... Peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy queues A new peer-reviewed publication in the prestigious Helicobacter journal (2026) confirms the clinical utility...
4/21/2026, 11:12 AM
by Ashwanga
12
This really good clarification by @JP199 to my own previous ramblings kept playing on my mind disturbingly. I have hyped up the company’s great openings (UK, India, South Korea, Chile) and their immense potential here. In my opinion, this “ketchup bottle effect” is still real. However...
2/17/2026, 6:19 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
8
Phew, wow, and oh my goodness. Huge and most humble thanks to both @JP199 and @Antti_Siltanen !! I admit I was completely in the dark that the situation regarding those receivables is this bad. This is starting to remind me of the TEM1V case one-to-one (1:1). As I have written, I...
2/16/2026, 3:43 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
8
At least in my opinion, the analysis (including management interviews) has highlighted this very well, which is why these receivables/cash flow have been monitored closely from the start If a risk materializes in this regard, no one can at least blame Inderes for ignoring the risk
2/16/2026, 8:24 AM
by JP199
7
Here are Antti’s comments on Biohit’s latest good news Biohit announced on Tuesday a new peer-reviewed study, the results of which supported the company’s value proposition regarding the benefit of the GastroPanel test in gastric cancer risk stratification and shortening treatment...
4/22/2026, 5:25 AM
by Sijoittaja-alokas
6
Warning: this post is pure speculation and irresponsible doom-mongering. I don’t actually have any idea what the most likely outcome will be. It could go well or very badly​ I can’t say anything more specific regarding the need for cash or possible share issues, but I personally ...
2/17/2026, 6:51 PM
by JP199
6
It has not provided an estimate. Sales in North and South America have been 0.1–0.2 MEUR per half-year in recent years. Based on the interview, they have more or less reached full speed in Chile already, so some conclusions regarding the scale can probably be drawn from the H1’26...
2/16/2026, 8:13 AM
by Antti Siltanen
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.8
2026

Interim report Q2'26

Regulatory press release6/5/2026, 3:00 PM

Constitutive meeting of Biohit Oyj’s Board of Directors

Biohit
Regulatory press release6/3/2026, 3:00 PM

Decisions of the Annual General Meeting of Biohit Oyj

Biohit
Regulatory press release5/6/2026, 12:45 PM

Correction: Notice of Biohit Oyj’s Annual General Meeting

Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/6/2026, 12:06 PM

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Regulatory press release5/6/2026, 12:00 PM

Notice of Biohit Oyj’s Annual General Meeting

Biohit
Study: Biohit's GastroPanel reduced waiting lists
Analyst Comment4/22/2026, 5:26 AM by
Antti Siltanen

Study: Biohit's GastroPanel reduced waiting lists

Endoscopy wait times were reduced by 87%.

Biohit
Press release4/21/2026, 11:00 AM

A peer-reviewed study confirms the value of the GastroPanel® test in reducing endoscopy waiting lists

Biohit
Regulatory press release4/1/2026, 11:00 AM

Biohit Plc B-shares Subscribed with Stock Options I 2021D

Biohit
US market roadmap for medical devices – a European perspective
Analyst Comment3/27/2026, 10:45 AM by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release3/18/2026, 7:30 AM

Publication of Biohit Oyj Annual Report 2025

Biohit
Regulatory press release3/18/2026, 7:30 AM

Publication of Biohit Oyj Remuneration Report 2025

Biohit
Press release3/11/2026, 11:00 AM

Change in the Biohit Oyj Management Team

Biohit
Biohit H2'25: Strong earnings – more moderate growth outlook
Research2/12/2026, 8:16 AM by
Antti Siltanen

Biohit H2'25: Strong earnings – more moderate growth outlook

Biohit’s revenue was in line with our estimate, and earnings exceeded it.

Biohit
Regulatory press release2/11/2026, 7:30 AM

BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2025

Biohit
Biohit Q4'25 preview: Back on the growth path from the middle of a sandstorm
Analyst Comment2/6/2026, 7:27 AM by
Antti Siltanen

Biohit Q4'25 preview: Back on the growth path from the middle of a sandstorm

We estimate revenue growth to have accelerated to 21% in late 2025 due to easing delivery difficulties in the Middle East.

Biohit
We take advantage of Biohit's January sale
Research1/16/2026, 7:32 AM by
Antti Siltanen

We take advantage of Biohit's January sale

Biohit's share price has fallen and the risk/reward ratio has become attractive again.

Biohit
Press release1/14/2026, 8:30 AM

Change in the Biohit Oyj’s Management Team

Biohit
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
New study on the benefits of GastroPanel in guiding treatment
Analyst Comment12/9/2025, 5:52 AM by
Antti Siltanen

New study on the benefits of GastroPanel in guiding treatment

Biohit announced a new clinical study on Monday.

Biohit
Press release12/8/2025, 8:30 AM

New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy

Biohit